| Value | ₹0.90 Cr |
|---|
BSE filing, NSE: ALIVUS. Summary written from the filing by ALFA Finder's alert engine.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,399.40
- Market cap
- ₹17,181 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 28.5×Sector 46.1×
- Promoter holding
- 74.85%-0.02% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Board Meeting Date
Alivus Life Sciences Ltd has scheduled a Board Meeting on October 29, 2026, to consider and approve its unaudited financial results for the period ended September 30, 2026.
Alivus Life Sciences Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.
Alivus Life Sciences Legal & Regulatory
Alivus Life Sciences Limited received a GST order for FY 2020-22 involving a tax demand and penalty of Rs. 0.51 Crore. The company is currently assessing an appeal.
- Value
- ₹0.51 Cr
Alivus Life Sciences Acquisition Worth ₹14.04 Cr
Alivus Life Sciences acquired a 9.21% stake in Torrent Urja 19 Private Limited for Rs. 14.04 Crore. The investment supports its renewable energy and carbon neutrality goals.
- Value
- ₹14.04 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Merger & Restructuring Worth ₹9.12 Cr
Alivus Life Sciences Limited will acquire a 76% stake in IQGEN-X Pharma Private Limited for approximately ₹9.12 Crore. This strategic acquisition enhances the company's CDMO solution offerings.
- Value
- ₹9.12 Cr
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr